The Pharmacokinetic-Pharmacodynamic Model of Azithromycin for Lipopolysaccharide-Induced Depressive-Like Behavior in Mice
Open Access
- 24 January 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (1) , e54981
Abstract
A mechanism-based model was developed to describe the time course of lipopolysaccharide-induced depressive-like behavior and azithromycin pharmacodynamics in mice. The lipopolysaccharide-induced disease progression was monitored by lipopolysaccharide, proinflammatory cytokines, and kynrenine concentration in plasma. The depressive-like behavior was investigated by forced swimming test and tail suspension test. Azithromycin was selected to inhibit the surge of proinflammatory cytokines induced by lipopolysaccharide. Disease progression model and azithromycin pharmacodynamics were constructed from transduction and indirect response models. A delay in the onset of increased proinflammatory cytokines, kynrenine, and behavior test compared to lipopolysaccharide was successfully characterized by series transduction models. The inhibition of azithromycin on proinflammatory cytokines was described by an indirect response model. After lipopolysaccharide challenging, the proinflammatory cytokines, kynrenine and behavior tests would peak approximately at 3, 12, and 24 h respectively, and then the time courses slowly declined toward a baseline state after peak response. During azithromycin administration, the peak levels of proinflammatory cytokines, kynrenine and behavior indexes decreased. Model parameters indicated that azithromycin significantly inhibited the proinflammatory cytokines level in plasma and improved the depressive-like behavior induced by inflammation. The integrated model for disease progression and drug intervention captures turnovers of proinflammatory cytokines, kynrenine and the behavior results in the different time phases and conditions.Keywords
This publication has 53 references indexed in Scilit:
- Monoamine depletion in psychiatric and healthy populations: reviewMolecular Psychiatry, 2003
- Cytokines and depression: The need for a new paradigmBrain, Behavior, and Immunity, 2003
- The enzyme indoleamine 2,3-dioxygenase is induced in the mouse brain in response to peripheral administration of lipopolysaccharide and superantigenBrain, Behavior, and Immunity, 2002
- Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapyMolecular Psychiatry, 2002
- Neurobehavioral Effects of Interferon-α in Cancer Patients Phenomenology and Paroxetine Responsiveness of Symptom DimensionsNeuropsychopharmacology, 2002
- Clarithromycin suppresses lipopolysaccharide-induced interleukin-8 production by human monocytes through AP-1 and NF-kappaB transcription factorsJournal of Antimicrobial Chemotherapy, 2002
- Anti-inflammatory effects of macrolide antibioticsEuropean Journal of Pharmacology, 2001
- Pharmacokinetic/Pharmacodynamic Modeling of Antipyretic and Anti-Inflammatory Effects of Naproxen in the RatThe Journal of Pharmacology and Experimental Therapeutics, 2001
- Comparative analysis of buprenorphine- and norbuprenorphine-induced analgesic effects based on pharmacokinetic-pharmacodynamic modeling.The Journal of Pharmacology and Experimental Therapeutics, 1995
- Blood–Brain Barrier Transport of Kynurenines: Implications for Brain Synthesis and MetabolismJournal of Neurochemistry, 1991